Renal Cell Carcinoma Clinical Trial
Official title:
Comparison of Peri-operative Outcomes of Laparoscopic or Robotic Partial Nephrectomy for Small Renal Mass: Transperitoneal vs Retroperitoneal Approach
Both laparoscopic partial nephrectomy (LPN) and robotic partial nephrectomy (RPN) can be
performed through transperitoneal (TP) or retroperitoneal (RP) approach. RP approach is less
utilized than TP approach because of technical difficulties when using rigid laparoscopic
instruments in the small space of retroperitoneum cavity. However, with advanced surgical
skills and thoughtful patient selection, RP approach may be associated with shorter
operative time (OT), less estimated blood loss (EBL), shorter length of hospital stay (LOS)
compared with TP approach.
Therefore, the investigators performed randomized control trial to compare the outcomes of
the two approaches (TP-LPN or RPN vs RP-LPN or RPN).
Partial nephrectomy is the standard treatment for small renal masses. The evolution of
minimally invasive partial nephrectomy led to widespread utilization of laparoscopic (LPN)
and robotic partial nephrectomy (RPN). Both LPN and RPN can be performed through
transperitoneal (TP) or retroperitoneal (RP) approach. RP approach is less utilized than TP
approach because of technical difficulties when using rigid laparoscopic instruments in the
small space of retroperitoneum cavity. However, with advanced surgical skills and thoughtful
patient selection, RP approach may be associated with shorter OT, less EBL, shorter LOS
compared with TP approach.
Therefore, the investigators performed randomized control trial to compare the outcomes of
the two approaches (TP-LPN or RPN vs RP-LPN or RPN).
The purpose of this study To compare the treatment outcomes of the transperitoneal and
retroperitoneal approach during LPN or RPN in treatment of small renal masses.
Inclusion criteria During the study period, a small renal mass (less than 4cm, T1a stage)
patients are going to underwent LPN or RPN.
Exclusion criteria
1. Patients who underwent radical nephrectomy
2. Patients with bilateral renal masses
3. Patients with a solitary kidney
4. Patients reject a written informed consent
5. Pregnancy
The number of target subjects More than 106 patients who meet the inclusion criteria
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04987203 -
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Completed |
NCT02853344 -
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
|
Phase 2 | |
Terminated |
NCT04088500 -
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05070637 -
Circulating Tumor Cell Reducing No-touch Nephrectomy
|
N/A | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Not yet recruiting |
NCT06049030 -
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01358721 -
Phase I Biomarker Study (BMS-936558)
|
Phase 1 | |
Active, not recruiting |
NCT04503148 -
Anesthesia and Cancer Study: Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Not yet recruiting |
NCT05808608 -
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03323710 -
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT02787915 -
DC1s-CTL Cellular Therapy for Renal Cell Carcinoma
|
Phase 1/Phase 2 |